Purpose: To evaluate the effects of single-nucleotide polymorphisms (SNP) in microRNA-related genes on clinical outcomes in patients with colorectal cancer (CRC) receiving first-line fluoropyrimidine-based chemotherapy.
Introduction
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths in Western countries (1) . Stage I disease usually can be cured by surgery alone, but patients with high-risk stage II, III, or IV disease are recommended for chemotherapy in the adjuvant or palliative setting (1-3). 5-Fluorouracil (5-FU) is the most frequently used chemotherapeutic agent for treating patients with CRCs. However, a substantial portion of patients with CRCs do not benefit from 5-FU-based treatment regimens, whereas treatment-related toxicity may be severe and dose-limiting (4, 5) . One strategy to improve the efficacy and reduce toxicity is to determine subgroups of patients who would have a poor or favorable prognosis after 5-FU-based chemotherapy, which may allow personalized treatment of patients with CRCs.
MicroRNA (miRNA) is a growing family of 21-to 23-nucleotide, endogenous, single-stranded noncoding RNAs that posttranscriptionally regulate the expression of target mRNA transcripts. A series of biogenesis steps yield mature miRNAs from pri-miRNA to pre-miRNA (6) (7) (8) . Given that impaired miRNA processing can result in a substantial decrease in mature miRNA levels (9) and many miRNAs target mRNA transcripts involved in cell proliferation, differentiation, and apoptosis (10) , it is conceivable that single-nucleotide polymorphisms (SNP) in genes of miRNA and of the miRNA biogenesis pathway may have effects on cancer risk, prognosis, and treatment response. SNPs are inherited genetic variations, can be easily assayed by highthroughput and reliable technology, capable of affecting gene expression or protein function, and therefore, are an alternative or complementary markers to tissue-based biomarkers. Several genome-wide association studies (GWAS) have identified at least 16 CRC susceptibility SNPs (11) (12) (13) (14) . However, because of the large sample size requirement and the heterogeneity of tumors and treatment, GWAS of clinical outcomes of CRCs or any other cancers has not been successfully conducted yet. Candidate gene approach is still the main approach in association studies of clinical outcomes. Several SNPs in the miRNA-related genes have been associated with the risk of cancers (15) (16) (17) . A premiRNA SNP (rs11614913) in mir196a2 was found to be associated with poor survival in individuals with nonsmall cell lung cancer (18) . An SNP in mir26a-1 was associated with disease response to irinotecan-based chemotherapy in patients with metastatic CRCs (19) . However, another study in Korean patients with surgically resected CRCs did not observe any association between the polymorphisms in miRNA biogenesis pathway and clinical outcomes (20) . To further dissect these issues, we have conducted a comprehensive study with regard to genetic variations in miRNA-related genes and clinical outcomes of patients with CRCs.
Materials and Methods

Study population and data collection
A total of 1,097 histologically confirmed patients with colorectal adenocarcinoma were recruited at the University of Texas MD Anderson Cancer Center between January 1990 and June 2008, with follow-up to January 2010. Among them, there were 741 newly diagnosed patients (diagnosed within 1 year), which was analyzed as a training set in this study. The remaining 356 patients had a long history (diagnosed > 1 year) of CRCs before recruitment, which was used as a replication set. A self-administered questionnaire was used for all patients to collect epidemiologic data including demographical characteristics, tobacco use, family history of cancer, and medical history. We reviewed patients' medical records to collect clinical information including date of diagnosis, performance status, clinical stage, tumor location, histologic grade, pathologic stage, treatment, and tumor recurrence/progression. Information on vital status was obtained from the medical records and Social Security Death Index (SSDI). Each patient donated 10 to 20 mL blood sample. All study participants signed an informed consent form, and the study was approved by the Institutional Review Board of MD Anderson Cancer Center.
SNP selection and genotyping
The selection of genes and SNPs has been described previously (16 24 SNPs in 11 genes related to miRNA biogenesis, 7 SNPs in 7 pre-miRNAs or mature miRNAs, and 10 SNPs in 8 pri-miRNAs. DNA was isolated from the peripheral blood samples using a QIAamp DNA extraction kit (Qiagen). SNP genotyping was done using the SNPlex assay, according to the manufacturer's instructions (Applied Biosystems). Internal quality controls and negative controls were used to ensure genotyping accuracy, and 5% of all samples were randomly selected and genotyped in duplicate, with 100% concordance. The average call rate for the SNPs was 98.8%. Two SNPs in pri-miRNAs (rs107822 and rs10425222) were excluded from further analysis due to the call rate being less than 95%.
Statistical analysis
The study endpoints were overall survival (OS), recurrence-free survival (RFS; for stage II and III patients), and progression-free survival (PFS; for stage IV patients). OS was calculated from pathologic diagnosis to death, regardless of the cause. PFS was defined as the time from pathologic diagnosis until disease progression or death, whichever occurred first. RFS was defined as the time from the date of pathologic diagnosis until first recurrence or death from any cause. Statistical analyses were conducted using STATA software (version 10, STATA Corporation). Cox proportional hazards model was used to estimate HRs and their 95% confidence intervals (CI) for the multivariate survival analyses in the training set and the replication set. The analyses were adjusted for age, gender, ethnicity, clinical stage, histologic grade, and if necessary, treatment modality and chemotherapy regimen. The Benjamini-Hochberg false discovery rate method was used to control for multiple comparisons with a threshold of q ¼ 0.05 (24) . Associations between genotypes and OS, PFS, and RFS were estimated using the Kaplan-Meier method, and statistical significance was determined using the log-rank test. We also evaluated the combined effects of the SNPs by the number of genotypes identified from the main effects analysis of single SNPs. All P values were 2-sided and a P 0.05 was considered statistically significant.
Translational Relevance
MicroRNA plays important roles in cellular proliferation, differentiation, and apoptosis. This study comprehensively evaluated the associations between singlenucleotide polymorphisms (SNP) in microRNA-related genes and clinical outcomes in patients with colorectal cancer (CRC) receiving first-line fluoropyrimidine-based chemotherapy and identified several biologically plausible individual predictors of recurrence and survival as well as cumulative effect in predicting patient outcomes. The validation and incorporation of the identified SNPs and interactions with the clinical variables may help identify patients with CRC with distinct prognosis to allow for personalized cancer therapy. There were 356 patients included in replication set. The mean age for stage I, II, III, and IV patients was 62.3 AE 2.0, 59.1 AE 1.0, 58.5 AE 0.84, and 55.2 AE 0.77, respectively. The median OS for the 4 stages was 63.2, 79.6, 71.8, and 36.6 months, respectively. These patients were diagnosed outside of MD Anderson Cancer Center over a year ago and came to MD Anderson Cancer Center for treatment due to potential tumor recurrence or progression; therefore, the recurrence, progression and death rates were higher than newly diagnosed patients (Table 1) .
Results
Patient characteristics
Training set
We assessed the association of each individual SNP with OS, PFS, and RFS using a multivariate Cox model, adjusting for age, gender, ethnicity, smoking status, tumor site, and histologic grade and stratified by stages (Table 2) . Among them, GEMIN4:rs7813 and rs910925 were in strong linkage disequilibrium (r 2 ¼ 0.99), thus we only included rs7813 in the subsequent analysis.
Because of the excellent prognosis and rare events of recurrence and death, we did not carry out analysis of stage I patients. Among 117 patients with stage II disease who received 5-FU-based chemotherapy, the most significant association with recurrence was conferred by the variant allele of RAN:rs14035 in a dose-dependent manner (perallele HR, 2.32; 95% CI, 1.28-4.21; P ¼ 0.005, q ¼ 0.06). The most significant SNP for survival was AGO2:rs4961280, the homozygous variant genotype was significantly associated with an increased risk of death (HR, 7.53; 95% CI, 1.46-38.83; P ¼ 0.02, q ¼ 0.18). Among 179 patients with stage III disease who received 5-FU-based chemotherapy, the variant-containing genotypes of mir608:rs4919510 exhibited increased risks of both recurrence (HR, 2.72; 95% CI, 1.38-5.33; P ¼ 0.004; q ¼ 0.03) and death (HR, 3.53; 95% CI, 1.42-8.73; P ¼ 0.006; q ¼ 0.05).
Moreover, these patients had a significantly shorter RFS (104.3 vs. >117.8 months, log-rank, P ¼ 0.01; Fig. 1A ) and OS (125.5 vs. >117.8 months, log-rank, P ¼ 0.01) than in those with the wild-type genotype. The GEMIN3:rs197412 and XPO5:rs11077 had highly significant associations with recurrence (HR, 2.07; 95% CI, 1.31-3.27; P ¼ 0.002; q ¼ 0.03; and HR, 0.38; 95% CI, 0.19-0.78; P ¼ 0.002; q ¼ 0.03, respectively), whereas mir604:rs2368392 and mir219-1: rs213210 showed highly significant associations with death (HR, 5.28; 95% CI, 1.57-17.74; P ¼ 0.007; q ¼ 0.05; and HR, 3.86; 95% CI, 1.33-11.22; P ¼ 0.01; q ¼ 0.06, respectively). This increase in risk of death resulted in a decreased OS for those with the variant-containing genotypes of mir219-1:rs213210 compared with patients carrying the homozygous wild-type genotype (64.8 vs. >117.8 months, log-rank, P ¼ 0.003; Fig. 2A ).
Among 218 patients with stage IV disease, the effects of the variant-containing genotypes of let-7f-2:rs17276588 and mir30c-1:rs16827546 on progression were significant after adjusting for multiple comparison (HR, 3.12; 95% CI, 1.61-6.06; P ¼ 0.0008, q ¼ 0.008; and HR, 2.12; 95% CI, 1.22-3.67; P ¼ 0.007; q ¼ 0.04, respectively). Two SNPs, Drosha:rs13078 (HR, 1.66; 95% CI, 1.09-2.52; P ¼ 0.02) and TRBP:rs784567 (HR, 1.59; 95% CI, 1.03-2.43; P ¼ 0.04), were associated with the risk of death but lost significance after adjusting for multiple comparison.
Replication set
Genotype data were analyzed in 53 stage II, 108 stage III, and 110 stage IV patients. None of the significant SNPs were validated in the replication set for stage II and IV patients; however, 2 SNPs, mir608:rs4919510 and mir219-1: rs213210, were confirmed for stage III patients (Table 2 for  top SNPs and Supplementary Tables S1 to S3 for complete results of all the analyzed SNPs in stage II-IV patients). As shown in Table 3 , the significant associations between mir608:rs4919510 and risk of both recurrence and death and the association between mir219-1:rs213210 and risk of death were confirmed in stage III patients in the replication set. Patients with the variant allele-containing genotypes of the mir608:rs4919510 showed increased risks of recurrence (HR, 1.64; 95% CI, 1.02-2.63; P ¼ 0.04) and death (HR, 1.93; 95% CI, 1.03-3.62; P ¼ 0.04) in the replication set. The pooled analysis HR was 1.65 (95% CI, 1.13-2.41; P ¼ 0.0097) for recurrence and 1.96 (95% CI, 1.19-3.21; P ¼ 0.0079) for death. Furthermore, compared with patients carrying the wild-type genotype, those with the variant-containing genotypes had a decrease in RFS in replication set (16.0 vs. 23.7 months, log-rank, P ¼ 0.02; Fig. 1B ) and combined data set (35.0 vs. 57.6 months, log-rank, P ¼ 0.0001; Fig. 1C ), respectively. The increase in risk of death also resulted in a decrease in OS in combined data set (74.8 vs.103.7 months, log-rank, P ¼ 0.0009; data not shown).
The variant-containing genotypes of the mir219-1: rs213210 showed consistent association with death in replication set (HR, 3.33; 95% CI, 1.39-7.98; P ¼ 0.007) and combined data set (HR, 3.22; 95% CI, 1.70-6.10; P ¼ 0.0003). These patients also had a significantly shorter OS than those with the wild-type genotype in replication set (50.4 vs.76.0 months, log-rank, P ¼ 0.03; Fig. 2B ) and combined data set (60.7 vs. 83.1 months, log-rank, P ¼ 0.003; Fig. 2C ).
Cumulative effect
Because the variant genotypes of mir608:rs4919510 and mir219-1:rs213210 were confirmed in stage III patients receiving adjuvant fluoropyrimidine-based therapy, we next conducted a joint analysis of these 2 SNPs (Table  4 ). There was a significant trend for the increased risk of death with the increasing number of variant genotypes in training set (P trend ¼ 0.0001) and replication set (P trend ¼ 0.003). In the combined data set, compared with patients without any variant genotype, patients carrying one variant genotype had a 2.51-fold increased risk of death (95% CI, 1.47-4.28; P ¼ 0.001), and the risk further increased to 5.6-fold (95% CI, 1.91-16.45; P ¼ 0.002) for patients carrying 2 variant genotypes (P trend ¼ 5.25 Â 10 À5 ).
Similar cumulative effect was also observed for recurrence in the training (P trend ¼ 0.0006), replication (P trend ¼ 0.01), and combined sets (P trend ¼ 0.001). In the combined data set, carrying 1 or 2 variant genotypes resulted in 1.67-fold (95% CI, 1.12-2.49; P ¼ 0.01) and 3.53-fold (95% CI, 1.51-8.26; P ¼ 0.004) increased risk of recurrence, respectively. When we conducted similar cumulative effect analysis using those significant SNPs in the testing set (Table 2 ) for stage II and IV patients, we observed similar trend of increased risk of recurrence/progression or death with increasing number of adverse genotypes (data not shown). Adjusted for age, gender, ethnicity, smoking status, tumor site, histologic grade, and treatment, for pooled analysis, also adjusted for study phase (training and replication).
Discussion
Our results reveal that mir608:rs4919510 and mir219-1: rs213210, alone or in combination, showed consistent association with clinical outcome for patients with stage III disease in the training and replication set. To our knowledge, this is the largest study to date to investigate the role of genetic variations in miRNA pathway in clinical outcomes for patients with CRCs.
Currently, tumor-node-metastasis (TNM) system remains the most commonly used criterion to predict prognosis and define the need for chemotherapy in patients with CRCs (25) . Fluoropyrimidine-based chemotherapy was routinely used in stage III disease, but recurrence rates remained high (26) . Risk stratification based on germline genotype status would provide information for individual chemotherapy. In the present study, mir608:rs4919510 was consistently associated with both recurrence and survival. A previous study has shown that the mir608:rs4919510 variant is associated with recurrence in patients with renal cell carcinoma (27) . The SNP rs4919510 is located in the mature mir608 sequence and was predicted to bind to mir608 target sites within the ACDC (adiponectin and collagen domain containing), CD4 (CD4 antigen), GHR (growth hormone receptor), RXRB (retinoic X receptor-b), and TP53 (tumor protein p53) genes with lower free energies than the wild-type allele (28) . These targets could affect CRC clinical outcome, for example, previous investigations reported that patients with stage III CRCs with tumors carrying TP53 mutation benefited from 5-FU-based postoperative chemotherapy (29, 30) . Therefore, it is conceivable that the variant miR608 could elicit different biologic activities of these target molecules that could affect CRC clinical outcome. It has been reported that the variant allele of mir219-1:rs213210 was associated with susceptibility to developing esophageal cancer (17) . We found that patients with CRCs carrying the variant genotypes of rs213210 had a worse survival, possibly through a mechanism of affecting the expression of mature mir219-1. The expression of mir219-1 was highly upregulated in metastatic hepatocellular carcinoma and was also capable of predicting patient survival and recurrence (31) . A previous study found that miR219 is a target of the CLOCK and BMAL1 complex and exhibits robust circadian rhythms of expression (32) , and another study showed that circadian clock protein BMAL1 coordinates in vivo tumor growth, S-phase progression, thymidylate synthase, and 5-FU therapeutic index (33) . It is tempting to speculate that circadian clock-related mechanism may partially explain the link between miR219 and recurrence in patients with stage III CRCs receiving 5-FU-based therapy. The functional consequence of mir219-1:rs213210 is not clear. Further studies are warranted to evaluate whether this SNP affects mir219-1 expression and processing, and the biologic mechanisms underlying the association of this SNP and recurrence.
We observed a clear and significant trend toward increased recurrence and death risk as the number of variant genotypes of mir608:rs4919510 and mir219-1:rs213210 and patients carrying 2 variant genotypes had a 5.6-fold increased risk of death. These results suggest that the cumulative influence of multiple SNPs was able to further enhance the separation between the patients with stage III disease who would have unfavorable prognosis following 5-FU-based adjuvant chemotherapy.
The effect of GEMIN3:rs197412, XPO5:rs11077, and mir604:rs2368392 was also highly significant in stage III disease, although the results were not confirmed in the replication set. The variant allele of GEMIN3:rs197412 has been shown to be associated with susceptibility to developing premalignant oral lesions (34) . XPO5:rs11077 was recently identified as a predictor of disease control rate for patients with colon cancer treated with 5-FU and irinotecan (19) . Polymorphisms affecting the expression of proteins involved in general miRNA biogenesis, such as GEMIN3 and XOP5, could alter global miRNA homeostasis and tissue-specific miRNA alterations (35) (36) (37) . The global repression of miRNA maturation has been shown to promote cellular transformation and tumorigenesis (9) . The functional consequence of SNPs in pre-miRNA sequences, such as mir604:rs2368392, has already been suggested to affect the processing and levels of the mature miRNA (18) . Given that variability in expression levels of miRNA may influence tumor progression and sensitivity to a fluoropyrimidine agent (19, 38) , these potential functional SNPs could emerge as potential predictors of prognosis and the efficacy of fluoropyrimidine.
For stage II disease, RAN:rs14035 was the most significant SNP associated with recurrence, although this SNP was not confirmed in the replication set. The key element in the nuclear export of pre-miRNAs is XPO5-RAN GTP-premiRNA heteroternary complex. The disruption in the premiRNA nucleocytoplasmic transport would impair the production of mature miRNAs in cancer cells (39) . RAN is overexpressed in most cancer cell lines including colon cancer, suggesting its role in tumor transformation (40) . Moreover, it was reported that RAN suppressed the activation of c-jun-NH 2 -kinase (JNK) and inhibited apoptosis induced by an anticancer drug (41). In patients with stage IV CRCs, let-7f-2:rs17276588 had significant predictive effect on progression in patients receiving fluoropyrimidine-based chemotherapy. This SNP remained significant after adjusting for multiple comparison in the training set and also showed the same direction in the replication set, although did not reach statistical significance. The let-7 family of miRNAs was found to regulate Ras activity by binding to the 3 0 -untranslated region (UTR) of the human Ras gene (42) . K-ras mutations have been associated with increased risk of relapse and death in patients with CRCs by the multicenter Colorectal Cancer Collaborative Group (RASCAL) study (43, 44) . Nakajima and colleagues showed an association between members of the let-7 family and responsiveness to the oral fluoropyrimidine S-1 (45) . Therefore, it is biologically plausible that SNPs in let-7 family of miRNAs affect CRC prognosis and treatment response.
Because the training and replication set split as we presented here may not be optimal due to the overrepresentation of recurrence and progression patients in the replication set, we also randomly split the entire data set into a training and a replication set and reconducted all the analyses, and the results were comparable with the current split (Supplementary Tables S4 and S5 for stage III patients as examples). In stage III patients, for survival, the mir608 SNP (P ¼ 0.019) and mir219-1 SNP (P ¼ 0.036) ranked the top 2 in P values in the new training set. In the new validation set, mir219-1 SNP was the most significant SNP and mir608 SNP was borderline. In pooled analysis, the mir219-1 SNP ranked the first and the mir608 SNP ranked the third. Because we believe that the original training set was cleaner and more optimal for initial screening, we presented the original results. Because our study is the first to comprehensively evaluate SNPs in miRNA pathways as prognostic factors for patients with CRCs receiving 5-FUbased chemotherapy, the data of pooled analysis of all SNPs would provide valuable information to investigators in the field who may conduct independent validation. The major strength of our study is the large population size that allowed us to conduct stage-stratified analyses in training and replication sets, which limited the confounding of tumor and treatment heterogeneity. The significant SNP mir608:rs4919510 remained significant after adjusting for multiple comparison, was validated in the replication set, and also showed consistent results for both recurrence and survival, therefore, this SNP is not likely to be falsepositive. An additional strength is the comprehensive clinical data for each of these patients. The main limitation of this study is that the replication set was not newly diagnosed patients and those patients came to MD Anderson mainly due to potential recurrence or progression. Therefore, the relative small and heterozygous population in the replication set may result in false-negatives, which may partially explain why none of the SNPs was validated in stage II and IV patients. For SNP mir219-1:rs213210, it was significant in both training and replication sets for OS in stage III patients and was borderline significant for recurrence in pooled analysis (HR, 1.63, 95% CI, 0.96-2.78, P ¼ 0.07; Supplementary Table S2 ). Given that this SNP has a low variant allele frequency (6%), we could not rule out that this SNP may be a chance finding. Larger patient cohort is warranted to further confirm this SNP.
In conclusion, we identified several plausible candidate SNPs in the miRNA pathway that are associated with clinical outcome in patients with CRCs and also observed significant cumulative effect of multiple SNPs in predicting prognosis in patients with CRCs receiving 5-FU-based chemotherapy. Further studies are needed to replicate these SNPs in independent populations, to functionally characterize the significant genetic variants, and to find the biologic mechanisms underlying the associations.
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